PTCT Ptc Therapeutics Inc

Price (delayed)

$25.98

Market cap

$1.96B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.66

Enterprise value

$2.5B

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally ...

Highlights
PTCT's gross profit is up by 15% YoY but it is down by 2.1% QoQ
Ptc Therapeutics's revenue has increased by 15% YoY but it has decreased by 2.5% from the previous quarter
Ptc Therapeutics's equity has shrunk by 196% YoY and by 16% QoQ
The company's debt has surged by 70% YoY

Key stats

What are the main financial stats of PTCT
Market
Shares outstanding
75.46M
Market cap
$1.96B
Enterprise value
$2.5B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.13
Earnings
Revenue
$798.18M
EBIT
-$619.35M
EBITDA
-$414.06M
Free cash flow
-$255.59M
Per share
EPS
-$8.66
Free cash flow per share
-$3.39
Book value per share
-$8.9
Revenue per share
$10.59
TBVPS
$10.01
Balance sheet
Total assets
$1.26B
Total liabilities
$1.93B
Debt
$704.35M
Equity
-$670.81M
Working capital
$48.24M
Liquidity
Debt to equity
-1.05
Current ratio
1.1
Quick ratio
0.94
Net debt/EBITDA
-1.3
Margins
EBITDA margin
-51.9%
Gross margin
94.1%
Net margin
-80.4%
Operating margin
-95.8%
Efficiency
Return on assets
-43.4%
Return on equity
N/A
Return on invested capital
-71%
Return on capital employed
-80.7%
Return on sales
-77.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PTCT stock price

How has the Ptc Therapeutics stock price performed over time
Intraday
0.27%
1 week
7.58%
1 month
-3.99%
1 year
-44.34%
YTD
-5.73%
QTD
-5.73%

Financial performance

How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$798.18M
Gross profit
$750.92M
Operating income
-$764.36M
Net income
-$641.7M
Gross margin
94.1%
Net margin
-80.4%
The company's operating income has shrunk by 103% YoY and by 6% QoQ
PTCT's operating margin has dropped by 77% year-on-year and by 9% since the previous quarter
The net income has contracted by 21% YoY and by 3.8% from the previous quarter
PTCT's gross profit is up by 15% YoY but it is down by 2.1% QoQ

Growth

What is Ptc Therapeutics's growth rate over time

Valuation

What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.13
The EPS is down by 16% year-on-year and by 2.7% since the previous quarter
Ptc Therapeutics's equity has shrunk by 196% YoY and by 16% QoQ
The price to sales (P/S) is 63% lower than the 5-year quarterly average of 6.6 and 32% lower than the last 4 quarters average of 3.6
Ptc Therapeutics's revenue has increased by 15% YoY but it has decreased by 2.5% from the previous quarter

Efficiency

How efficient is Ptc Therapeutics business performance
Ptc Therapeutics's ROA has decreased by 45% YoY and by 9% from the previous quarter
The ROIC has contracted by 31% YoY
The ROS is down by 21% year-on-year and by 8% since the previous quarter

Dividends

What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTCT.

Financial health

How did Ptc Therapeutics financials performed over time
The total assets is 35% less than the total liabilities
The total assets has contracted by 20% YoY and by 6% from the previous quarter
The quick ratio has declined by 13% since the previous quarter and by 4.1% year-on-year
Ptc Therapeutics's equity has shrunk by 196% YoY and by 16% QoQ
The company's debt has surged by 70% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.